# US 2026/0091114 A1 · Chimeric antigen receptors binding nectin-4

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091114 A1
- Document ID: US20260091114A1
- Status: Published application
- Kind: A1
- Application number: 19/112,145
- Filed: 2023-09-14
- Published: 2026-04-02
- Earliest claimed: 2022-09-14
- Assignees: Fred Hutchinson Cancer Center
- Applicants: Fred Hutchinson Cancer Center
- Inventors: John K. Lee; Li-Ting Wu
- Web page: https://patentgrep.com/patent/US20260091114A1

## CPC

- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4254: {Adhesion molecules, e.g. NRCAM, EpCAM or cadherins}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 2239/46: characterised by the cancer treated
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Chimeric antigen receptors (CAR) with a binding domain that binds Nectin-4 are disclosed. The Nectin-4 binding domain can be derived from the murine antibody M22-321b41.1. The CAR disclosed herein can be expressed by an immune cell to be used in the treatment of Nectin-4-expressing cancers, such as bladder, breast, ovarian, esophageal, lung, colorectal, or pancreatic cancers.

## Claims

### Claim 1

A chimeric antigen receptor (CAR) comprising, when expressed by a cell,
an extracellular component comprising a Nectin-4 binding domain;
an intracellular component comprising an effector domain; and
a transmembrane domain linking the extracellular component to the intracellular component.

### Claim 2 (depends on 1)

The CAR of claim 1, wherein the Nectin-4 binding domain has a complementarity determining region (CDR) set of antibody M22-321b41.1, according to North, Kabat, IMGT, Chothia, or Contact.

### Claim 3 (depends on 1)

The CAR of claim 1, wherein the Nectin-4 binding domain comprises a single chain variable fragment (scFv).

### Claim 4 (depends on 3)

The CAR of claim 3, wherein the scFv has a variable heavy chain with at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 57 and a variable light chain with at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 58.

### Claim 5 (depends on 3)

The CAR of claim 3, wherein the scFv has a variable heavy chain that has the sequence as set forth in SEQ ID NO: 57 and a variable light chain that has the sequence as set forth in SEQ ID NO: 58.

### Claim 6 (depends on 3)

The CAR of claim 3, wherein the scFv has at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 53 or SEQ ID NO: 55.

### Claim 7 (depends on 3)

The CAR of claim 3, wherein the scFv has the sequence as set forth in SEQ ID NO: 53 or SEQ ID NO: 55.

### Claim 8 (depends on 3)

The CAR of claim 3, wherein the scFv has a variable heavy chain that is encoded by a sequence with at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 59 and a variable light chain that is encoded by a sequence with at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 60.

### Claim 9 (depends on 3)

The CAR of claim 3, wherein the scFv has a variable heavy chain that is encoded by the sequence as set forth in SEQ ID NO: 59 and a variable light chain that is encoded by the sequence as set forth in SEQ ID NO: 60.

### Claim 10 (depends on 3)

The CAR of claim 3, wherein the scFv is encoded by a sequence having at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 54 or SEQ ID NO: 56.

### Claim 11 (depends on 3)

The CAR of claim 3, wherein the scFv is encoded by the sequence as set forth in SEQ ID NO: 54 or SEQ ID NO: 56.

### Claim 12 (depends on 1)

The CAR of claim 1, wherein the extracellular component further comprises a spacer.

### Claim 13 (depends on 12)

The CAR of claim 12, wherein the spacer is 230 amino acids or less.

### Claim 14 (depends on 12)

The CAR of claim 12, wherein the spacer consists of a hinge region, CH2 domain, and CH3 domain of IgG4.

### Claim 15 (depends on 14)

The CAR of claim 14, wherein the IgG4 is human IgG4.

### Claim 16 (depends on 12)

The CAR of claim 12, wherein the spacer has at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 23.

### Claim 17 (depends on 12)

The CAR of claim 12, wherein the spacer has the sequence as set forth in SEQ ID NO: 23.

### Claim 18 (depends on 12)

The CAR of claim 12, wherein the spacer is encoded by a sequence having at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 24.

### Claim 19 (depends on 12)

The CAR of claim 12, wherein the spacer is encoded by the sequence as set forth in SEQ ID NO: 24.

### Claim 20 (depends on 12)

The CAR of claim 12, wherein the spacer is 160 amino acids or less.

### Claim 21 (depends on 12)

The CAR of claim 12, wherein the spacer consists of a hinge region and CH3 domain of IgG4.

### Claim 22 (depends on 21)

The CAR of claim 21, wherein the IgG4 is human IgG4.

### Claim 23 (depends on 12)

The CAR of claim 12, wherein the spacer has at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 21.

### Claim 24 (depends on 12)

The CAR of claim 12, wherein the spacer has the sequence as set forth in SEQ ID NO: 21.

### Claim 25 (depends on 12)

The CAR of claim 12, wherein the spacer is encoded by a sequence having at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 22.

### Claim 26 (depends on 12)

The CAR of claim 12, wherein the spacer is encoded by the sequence as set forth in SEQ ID NO: 22.

### Claim 27 (depends on 12)

The CAR of claim 12, wherein the spacer is 15 amino acids or less.

### Claim 28 (depends on 12)

The CAR of claim 12, wherein the spacer consists of the hinge region of IgG4.

### Claim 29 (depends on 28)

The CAR of claim 28, wherein the IgG4 is human IgG4.

### Claim 30 (depends on 12)

The CAR of claim 12, wherein the spacer has at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 9.

### Claim 31 (depends on 12)

The CAR of claim 12, wherein the spacer has the sequence as set forth in SEQ ID NO: 9.

### Claim 32 (depends on 12)

The CAR of claim 12, wherein the spacer is encoded by a sequence having at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12.

### Claim 33 (depends on 12)

The CAR of claim 12, wherein the spacer is encoded by the sequence as set forth in SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12.

### Claim 34 (depends on 1)

The CAR of claim 1, wherein the effector domain comprises all or a portion of a CD3ζ signaling domain; all or a portion of a 4-1BB signaling domain; all or a portion of a CD28 signaling domain; all or a portion of the CD3ζ signaling domain and the 4-1BB signaling domain; all or a portion of the CD3ζ signaling domain and all or a portion of the CD28 signaling domain; or all or a portion of the CD3ζ signaling domain, all or a portion of the 4-1BB signaling domain, and all or a portion of the CD28 signaling domain.

### Claim 35 (depends on 34)

The CAR of claim 34, wherein the effector domain comprises all or a portion of the CD3ζ signaling domain and all or a portion of the 4-1BB signaling domain.

### Claim 36 (depends on 34)

The CAR of claim 34, wherein the effector domain comprises all or a portion of the CD3ζ signaling domain, all or a portion of the 4-1BB signaling domain, and all or a portion of the CD28 signaling domain.

### Claim 37 (depends on 34)

The CAR of claim 34, wherein the CD3ζ signaling domain has at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 38, SEQ ID NO: 39, and/or SEQ ID NO: 40.

### Claim 38 (depends on 34)

The CAR of claim 34, wherein the CD3ζ signaling domain has the sequence as set forth in SEQ ID NO: 38, SEQ ID NO: 39, or SEQ ID NO: 40.

### Claim 39 (depends on 34)

The CAR of claim 34, wherein the CD3ζ signaling domain is encoded by a sequence having at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 41 and/or SEQ ID NO: 42.

### Claim 40 (depends on 34)

The CAR of claim 34, wherein the CD3ζ signaling domain is encoded by the sequence set forth in SEQ ID NO: 41 or SEQ ID NO: 42.

### Claim 41 (depends on 34)

The CAR of claim 34, wherein the 4-1BB signaling domain has at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 32, SEQ ID NO: 33, and/or SEQ ID NO: 34.

### Claim 42 (depends on 34)

The CAR of claim 34, wherein the 4-1BB signaling domain has the sequence as set forth in SEQ ID NO: 32, SEQ ID NO: 33, or SEQ ID NO: 34.

### Claim 43 (depends on 34)

The CAR of claim 34, wherein the 4-1BB signaling domain is encoded by a sequence having at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 35, SEQ ID NO: 36, and/or SEQ ID NO: 37.

### Claim 44 (depends on 34)

The CAR of claim 34, wherein the 4-1BB signaling domain is encoded by the sequence as set forth in SEQ ID NO: 35, SEQ ID NO: 36, or SEQ ID NO: 37.

### Claim 45 (depends on 34)

The CAR of claim 34, wherein the CD28 signaling domain has at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 110.

### Claim 46 (depends on 34)

The CAR of claim 34, wherein the CD28 signaling domain has the sequence as set forth in SEQ ID NO: 110.

### Claim 47 (depends on 34)

The CAR of claim 34, wherein the CD28 signaling domain is encoded by a sequence having at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 111.

### Claim 48 (depends on 34)

The CAR of claim 34, wherein the CD28 signaling domain is encoded by the sequence as set forth in SEQ ID NO: 111.

### Claim 49 (depends on 1)

The CAR of claim 1, wherein the transmembrane domain comprises a CD28 transmembrane domain.

### Claim 50 (depends on 49)

The CAR of claim 49, wherein the CD28 transmembrane domain has at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 25, SEQ ID NO: 26, and/or SEQ ID NO: 27.

### Claim 51 (depends on 49)

The CAR of claim 49, wherein the CD28 transmembrane domain has the sequence as set forth in SEQ ID NO: 25, SEQ ID NO: 26, or SEQ ID NO: 27.

### Claim 52 (depends on 49)

The CAR of claim 49, wherein the CD28 transmembrane domain is encoded by a sequence having at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 117, and/or SEQ ID NO: 119.

### Claim 53 (depends on 49)

The CAR of claim 49, wherein the CD28 transmembrane domain is encoded by the sequence as set forth in SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 117, or SEQ ID NO: 119.

### Claim 54 (depends on 1)

The CAR of claim 1, wherein the Nectin-4 binding domain comprises a Nectin-4 scFv, the intracellular component comprises the CD3ζ signaling domain and the 4-1BB signaling domain, and the transmembrane domain comprises the CD28 transmembrane domain.

### Claim 55 (depends on 1)

The CAR of claim 1, wherein the Nectin-4 binding domain comprises a Nectin-4 scFv, the intracellular component comprises a CD3ζ signaling domain, a 4-1BB signaling domain, and a CD28 signaling domain, and the transmembrane domain comprises a CD28 transmembrane domain.

### Claim 56 (depends on 1)

The CAR of claim 1, having at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 2.

### Claim 57 (depends on 1)

The CAR of claim 1, having the sequence as set forth in SEQ ID NO: 2.

### Claim 58 (depends on 1)

The CAR of claim 1, encoded by a sequence having at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 3.

### Claim 59 (depends on 1)

The CAR of claim 1, encoded by the sequence as set forth in SEQ ID NO: 3.

### Claim 60 (depends on 1)

The CAR of claim 1, further comprising a self-cleaving polypeptide.

### Claim 61 (depends on 60)

The CAR of claim 60, wherein the self-cleaving polypeptide is a porcine teschovirus-1 (P2A), Thosea asigna virus (T2A), equine rhinitis A virus (E2A), foot-and-mouth disease virus (F2A), or variants thereof.

### Claim 62 (depends on 60)

The CAR of claim 60, wherein the self-cleaving polypeptide is a T2A self-cleaving polypeptide.

### Claim 63 (depends on 1)

The CAR of claim 1, further comprising a transduction marker.

### Claim 64 (depends on 63)

The CAR of claim 63, wherein the transduction marker is a truncated epidermal growth factor receptor (EGFRt).

### Claim 65 (depends on 64)

The CAR of claim 64, wherein the EGFRt has at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 50.

### Claim 66 (depends on 64)

The CAR of claim 64, wherein the EGFRt has the sequence as set forth in SEQ ID NO: 50.

### Claim 67 (depends on 64)

The CAR of claim 64, wherein the EGFRt is encoded by a sequence having at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 51.

### Claim 68 (depends on 64)

The CAR of claim 64, wherein the EGFRt is encoded by the sequence as set forth in SEQ ID NO: 51.

### Claim 69 (depends on 1)

The CAR of claim 1, further comprising a tag cassette or a suicide switch.

### Claim 70 (depends on 1)

The CAR of claim 1, further comprising a multimerization domain.

### Claim 71 (depends on 1)

A genetic construct encoding the CAR of claim 1.

### Claim 72 (depends on 71)

The genetic construct of claim 71, wherein the genetic construct has at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 1 and/or SEQ ID NO: 3.

### Claim 73 (depends on 71)

The genetic construct of claim 71, wherein the genetic construct has the sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 3.

### Claim 74 (depends on 71)

A nanoparticle encapsulating the genetic construct of claim 71.

### Claim 75 (depends on 1)

A population of cells genetically modified to express the CAR of claim 1.

### Claim 76 (depends on 75)

The population of cells of claim 75, wherein the population of cells comprises autologous cells or allogeneic cells in reference to a subject.

### Claim 77 (depends on 75)

The population of cells of claim 75, wherein the population is in vivo or ex vivo.

### Claim 78 (depends on 75)

The population of cells of claim 75, wherein the population comprises T-cells, B cells, natural killer (NK) cells, NK-T-cells, monocytes/macrophages, hematopoietic stem cells (HSC), and/or hematopoietic progenitor cell (HPCs).

### Claim 79 (depends on 75)

The population of cells of claim 75, wherein the population comprises CD4+ T-cells and CD8+ T-cells.

### Claim 80 (depends on 75)

The population of cells of claim 75, wherein the population comprises a 1:1 ratio of CD4+ T-cells to CD8+ T-cells.

### Claim 81 (depends on 1)

A formulation comprising (i) cells genetically modified to express a CAR of claim 1 and (ii) a pharmaceutically acceptable carrier.

### Claim 82 (depends on 81)

A method of providing an immune response against Nectin-4-expressing cells in a subject in need thereof comprising administering a therapeutically effective amount of the formulation of claim 81 to the subject thereby providing an immune response against Nectin-4-expressing cells in the subject.

### Claim 83 (depends on 82)

The method of claim 82, wherein the Nectin-4-expressing cells are cancer cells.

### Claim 84 (depends on 82)

The method of claim 82, wherein the immune response results in killing of the cancer cells.

### Claim 85 (depends on 84)

The method of claim 84, wherein the cancer cells are bladder cancer cells, breast cancer cells, ovarian cancer cells, esophageal cancer cells, lung cancer cells, colorectal cancer cells, head and neck squamous cell cancer cells, or pancreatic cancer cells.

### Claim 86 (depends on 85)

The method of claim 85, wherein the bladder cancer cells are urothelial carcinoma cells.

### Claim 87 (depends on 85)

The method of claim 85, wherein the breast cancer cells are triple-negative breast cancer (TNBC) cells or basal breast cancer cells.

### Claim 88 (depends on 82)

The method of claim 82, wherein the administering a therapeutically effective amount comprises administering intravesically, intravenously, intradermally, intraarterially, intraparenterally, intranodally, intralymphatically, intraperitoneally, intralesionally, intraprostatically, intravaginally, intrarectally, topically, intrathecally, intratumorally, intramuscularly, or subcutaneously.

### Claim 89 (depends on 82)

The method of claim 82, wherein the administering a therapeutically effective amount comprises administering intravesically.

### Claim 90 (depends on 89)

The method of claim 89, wherein the administering intravesically comprises instilling the formulation into the bladder of the subject for a select dwell time.

### Claim 91 (depends on 90)

The method of claim 90, wherein the select dwell time comprises 15 minutes to two hours.

### Claim 92 (depends on 89)

The method of claim 89, wherein the method further comprises emptying the bladder of the subject before instilling the formulation into the bladder of the subject.

### Claim 93 (depends on 89)

The method of claim 89, wherein the method further comprises administering an anticholinergic.
